Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: Results from the international SCHOLAR-5 study Journal Article
| Authors: | Ghione, P.; Palomba, M. L.; Ghesquieres, H.; Bobillo, S.; Patel, A. R.; Nahas, M.; Kanters, S.; Deighton, K.; Hatswell, A.; Ma, L.; Limbrick-Oldfield, E. H.; Snider, J. T.; Wade, S. W.; Riberio, M. T.; Radford, J.; Beygi, S.; Gribben, J. |
| Article Title: | Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: Results from the international SCHOLAR-5 study |
| Abstract: | The SCHOLAR-5 study examines treatment patterns and outcomes of real-world follicular lymphoma (FL) patients on 3rd line of treatment (LoT) or higher, for whom existing data are limited. SCHOLAR-5 is a retrospective cohort study using data from adults (≥ 18 years) with grade 1-3a FL, initiating ≥3rd LoT after June 2014 at major lymphoma centers in the US and Europe. Objective response rate (ORR), complete response (CR), progression-free survival (PFS) and overall survival (OS) were analyzed by LoT. Time-to-event outcomes were assessed using Kaplan-Meier methods. Of 128 patients, 87 initiated 3rd LoT, 63 initiated 4th LoT, and 47 initiated 5th LoT. At 1st eligible LoT, 31% progressed within 24-months of 1st LoT anti-CD20 combination therapy, 28% had prior autologous stem cell transplantation, and 31% were refractory to the previous LoT. The most common regimen in each LoT was chemoimmunotherapy; however, experimental drugs were increasingly used at later LoT. In the US, anti-CD20 monotherapy was more common at ≥3rd LoT compared to Europe, where stem cell transplants were more common. ORR at 3rd LoT was 68% (CR 44%), but decreased after each LoT to 37% (CR 22%) in ≥5 LoT. Median OS and PFS at 3rd LoT were 68 and 11 months, respectively, and reduced to 43 and 4 months at ≥5 LoT. Treatments were heterogenous at each LoT in both the US and Europe. Few FL patients achieved CR in later LoT, and duration of response and survival diminished with each subsequent line. ©2023 Ferrata Storti Foundation Published under a CC BY-NC license. |
| Keywords: | adult; treatment outcome; aged; disease-free survival; retrospective studies; unclassified drug; major clinical study; overall survival; lenalidomide; monotherapy; systemic therapy; disease free survival; chemotherapy; rituximab; follow up; antineoplastic agent; sensitivity analysis; progression free survival; computer assisted tomography; neoplasm recurrence, local; antineoplastic combined chemotherapy protocols; cohort analysis; relapse; bendamustine; autologous stem cell transplantation; hematopoietic stem cell transplantation; retrospective study; biopsy; histology; survival time; nonhodgkin lymphoma; immunotherapy; multicenter study; tumor recurrence; follicular lymphoma; marginal zone lymphoma; lymphoma, follicular; transplantation, autologous; geography; drug; autotransplantation; clinical outcome; procedures; cd20 antibody; cd19 antibody; idelalisib; follicular lymphoma international prognostic index; very elderly; humans; prognosis; human; male; female; article; ecog performance status; chimeric antigen receptor t-cell immunotherapy; cyclophosphamide plus doxorubicin plus prednisolone plus vincristine; cyclophosphamide plus prednisolone plus vincristine; line of treatment |
| Journal Title: | Haematologica |
| Volume: | 108 |
| Issue: | 3 |
| ISSN: | 0390-6078 |
| Publisher: | Ferrata Storti Foundation |
| Date Published: | 2023-03-01 |
| Start Page: | 822 |
| End Page: | 832 |
| Language: | English |
| DOI: | 10.3324/haematol.2022.281421 |
| PUBMED: | 36263843 |
| PROVIDER: | scopus |
| PMCID: | PMC9973479 |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work